Dear stakeholders,
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of ALXN1840 for treating Wilson disease TSID9950.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 9950 |
Project Team
| Project lead | Abbie Stephens |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 October 2023 | Suspended. Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of ALXN1840 for treating Wilson disease TSID9950. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme |
For further information on our processes and methods, please see our CHTE processes and methods manual